Tyrosine Kinase 2 Inhibitor

Tyrosine Kinase 2 Inhibitors

Parapsoriasis

<section class="Section" data-sectioncode="34089-3"><a name="ID_3a25c5bb-1c40-49bc-a2bd-e9a06aeb4dcd"></a><a name="section-9"></a><p></p><h1>11 DESCRIPTION </h1><p class="First">Deucravacitinib is a tyrosine kinase 2 (TYK2) inhibitor and is described chemically as: </p><p>6-(cyclopropanecarbonylamido)-4-[2-methoxy-3-(1-methyl-1,2,4-triazol-3-yl)anilino]-N-(trideuteriomethyl)pyridazine-3-carboxamide.</p><p>The molecular formula is C<span class="Sub">20</span>H<span class="Sub">19</span>D<span class="Sub">3</span>N<span class="Sub">8</span>O<span class="Sub">3</span> and the molecular weight of the free base is 425.47. Deucravacitinib has the structural formula:</p><div class="Figure"><a name="id-1792747554"></a><img alt="chem-structure" src="chem-structure.jpg"/></div><p>Deucravacitinib is a white to yellow powder. The solubility of deucravacitinib is pH dependent. Solubility decreases with increasing pH.</p><p>SOTYKTU (deucravacitinib) tablets are supplied in 6 mg strength for oral administration. Each tablet contains deucravacitinib as the active ingredient and the following inactive ingredients: anhydrous lactose, croscarmellose sodium, hypromellose acetate succinate, magnesium stearate, microcrystalline cellulose, and silicon dioxide. In addition, the film coating Opadry<span class="Sup">®</span> II Pink contains the following inactive ingredients: iron oxide red, iron oxide yellow, polyethylene glycol, polyvinyl alcohol, talc, and titanium dioxide.</p></section>

SOTYKTU

deucravacitinib

deucravacitinib 6 MG Oral Tablet

Sotyktu

deucravacitinib 6 MG Oral Tablet [Sotyktu]

Psoriasis (PsO)

Psoriatic Arthritis (PsA)

Ankylosing Spondylitis (AS)

Nonradiographic Axial Spondyloarthritis

Taltz

Juvenile Idiopathic Arthritis

Hidradenitis Suppurativa (HS)

Cosentyx

Siliq

Tremfya

Crohn's Disease (CD)

Ulcerative Colitis (UC)

Stelara

Skyrizi

Ilumya

Migraine

Cluster Headache

Migraine Prevention

Emgality

Qulipta

Acute Migraine

Ubrelvy

Nurtec ODT

Vyepti

Aimovig

Ajovy

Breast Cancer: HR+ (HER2-)

Verzenio

Ibrance

Kisqali

Atopic Dermatitis (Eczema)

Cibinqo

Eucrisa

Asthma (injectable)

Asthma OCS Dependent

Nasal Polyposis

Eosinophilic Esophagitis (EoE)

Prurigo Nodularis

Dupixent

Opzelura

Adbry

NSCLC ALK+ OR ROS1+ Disease

Lorbrena

Alecensa

Alunbrig

NSCLC cMET Mutation

Xalkori

Rheumatoid Arthritis (RA)

Xeljanz

Uveitis

Graft Versus Host Disease (GVHD)

Orencia

COVID-19 Treatment

Alopecia Areata

Olumiant

Multiple Sclerosis (MS)

Secondary Progressive Multiple Sclerosis

Zeposia

Rinvoq

Entyvio

Report Adverse Event 

Prescribing Information 

Medication Guide 

Submit MSL Request 

Pharmacy List 

Coverage Authorization Request 

Coverage Authorization Appeals 

Letter of Medical Necessity 

Formulary Exception Letter 

Coverage Reverification Letter 

Sotkyu 360 Start Form 

Enroll in Patient Savings Program 

Free Trial Offer 

Bridge Program 

Sotyktu Access & Reimbursement Guide 

Reimbursement Information 

Patient Authorization - Esign Form 

Other HCP Resources 

About Sotyktu

Sotyktu Start Guide 

Taking Sotyktu 

Side Effects 

Sotyktu Brochure 

Doctor Discussion Guide 

My Experience Tracker 

Patient Resources 

Sotyktu 360 Support 

Instructions For Use: Plaque Psoriasis 